FRMSP Business Summary

Formosa Pharmaceuticals (FRMSP) is a clinical-stage biopharmaceutical company that generates revenue primarily through global licensing agreements, upfront payments, and milestone-based royalties. The company’s business model centers on its proprietary Activus Pure Nanoparticle Technology (APNT®) platform, which enhances the bioavailability and stability of poorly soluble active ingredients. Its primary business segment is ophthalmology, led by its flagship FDA-approved product BYQLOVI™ (APP13007), a clobetasol propionate nanosuspension for treating post-operative ocular inflammation and pain. FRMSP also maintains active pipelines in oncology, specifically antibody-drug conjugate (ADC) biosimilars like TSY-0110, and anti-infectives. Within the ophthalmic steroid market, FRMSP competes directly with established players such as Bausch + Lomb (Lotemax), Alcon (Durezol), and Kala Pharmaceuticals (Inveltys). FRMSP distinguishes itself as a disruptive entrant by offering the first new ophthalmic steroid in over 15 years, featuring a superior twice-daily dosing regimen compared to the four-times-daily standard of legacy competitors. Founded in 2010 by Dr. Chen-Yu (CY) Cheng, the company is led by a management team with deep pedigree in medicinal chemistry and global drug development. Dr. Cheng, who also founded Formosa Laboratories, serves as Chairman and brings over 35 years of industry experience from DuPont and National Taiwan University. The executive leadership is headed by President and CEO Dr. Erick Co, a medicinal chemist with over 25 years of experience at Exelixis, Takeda, and ScinoPharm Taiwan. The strategic direction is further supported by Chief Business & Strategy Officer Dr. Artemis Wu. The company’s board and investor base feature prominent industry figures, including Dr. Jo Shen, a venture partner at Vivo Capital and co-founder of ScinoPharm, and Dr. Hong-Jen Chang, Chairman of YFY Biotech Management Company. This leadership structure leverages strong ties to Formosa Laboratories for bioconjugation and manufacturing scale-up, positioning the firm as a key hub for high-potency drug formulation in the Asia-Pacific region.